Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$661000.0.

  • Enanta Pharmaceuticals' Non Operating Income fell 17897.25% to -$661000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $302000.0, marking a year-over-year decrease of 9222.25%. This contributed to the annual value of $1.8 million for FY2025, which is 5388.16% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Non Operating Income stood at -$661000.0 for Q4 2025, which was down 17897.25% from -$282000.0 recorded in Q3 2025.
  • Enanta Pharmaceuticals' Non Operating Income's 5-year high stood at $1.9 million during Q2 2023, with a 5-year trough of -$661000.0 in Q4 2025.
  • For the 5-year period, Enanta Pharmaceuticals' Non Operating Income averaged around $709550.0, with its median value being $667500.0 (2024).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Non Operating Income surged by 62039.22% in 2023 and then tumbled by 17897.25% in 2025.
  • Enanta Pharmaceuticals' Non Operating Income (Quarter) stood at $258000.0 in 2021, then soared by 284.88% to $993000.0 in 2022, then fell by 13.7% to $857000.0 in 2023, then fell by 2.33% to $837000.0 in 2024, then crashed by 178.97% to -$661000.0 in 2025.
  • Its Non Operating Income was -$661000.0 in Q4 2025, compared to -$282000.0 in Q3 2025 and $667000.0 in Q2 2025.